openPR Logo
Press release

Pegfilgrastim Biosimilar Market to Witness a Pronounce Growth During 2018 to 2028

08-13-2018 03:20 PM CET | Advertising, Media Consulting, Marketing Research

Press release from: Fact.MR

Pegfilgrastim Biosimilar Market to Witness a Pronounce Growth

Biosimilar is a medical product that is almost an identical copy of an existing drug manufactured by a different company. They require independent approval through clinical trials. The Biosimilar market is an expanding market. Approximately 30% of drugs sold globally are biopharma drugs. 40% of prescription drug spending in the US is on biologic drugs. Filgrastim is used as a medication for treating low levels of blood neutrophils caused by chemotherapy, HIV/AIDS, radiation poisoning or some other unknown source. It stimulates the growth of white blood cells which are used to fight infections in the body. Pegfilgrastim biosimilar is an existing medical product that fights low white blood cell levels. The Pegfilgrastim biosimilar market is an expanding market in the US. Pegfilgrastim biosimilar is the long-acting drug form of Filgrastim. It has a human half-life of approximately 15-80 hours, which is more than the parent Filgrastim. Pegfilgrastim biosimilar named Fulphila (Pegfilgrastim-jmdb), produced by Biocon/Mylan, collaboration has recently been approved by the US FDA as the first Biosimilar to Neulasta, which is an existing medical product used to treat low blood neutrophils levels. Pegfilgrastim Biosimilar is almost identical to Neulasta, which was the first drug used to fight low neutrophils levels.

Pegfilgrastim Biosimilar Market: Drivers

Increasing prevalence of diseases, such as cancer and HIV/AIDS, will drive the growth of the Pegfilgrastim Biosimilar market. Pegfilgrastim biosimilar also fights infections and controls low blood neutrophils level in patients having undergone chemotherapy, radiation poisoning, etc. Pegfilgrastim Biosimilar is cheaper than Pegfilgrastim, which might also contribute to the expansion of the Pegfilgrastim Biosimilar market over the forecast period. However, side effects related to Pegfilgrastim Biosimilar, such as bone pain, acute respiratory distress syndrome, rupture of the spleen and other allergic reactions, might hinder the growth of Pegfilgrastim Biosimilar market. Reimbursement policies for Biosimilar in the market are also not well appreciated and could restrain the growth of Pegfilgrastim Biosimilar market over the forecast period.

Request TOC of this Report @ https://www.factmr.com/connectus/sample?flag=T&rep_id=1494

Pegfilgrastim Biosimilar Market: Segmentation

The global Pegfilgrastim Biosimilar Market can be segmented on the basis of application type, distribution channels and geography.

Based on application type, the global Pegfilgrastim Biosimilar Market is segmented as:

Chemotherapy Treatment
Myelosuppressive Chemotherapy Treatment
Induction or Consolidation Chemotherapy Treatment
Transplantation
Bone Marrow Transplantation
Peripheral Blood Progenitor Cell Transplantation
Based on distribution channels, the global Pegfilgrastim Biosimilar Market is segmented as:

Hospital pharmacies
Retail pharmacies
Mail-Order pharmacies
Based on geography, the global Pegfilgrastim Biosimilar Market is segmented as:

North America
Latin America
Europe
CIS & Russia
Japan
APEJ
Middle East & Africa
Pegfilgrastim Biosimilar Market: Overview

Increasing incidences of cancer are leading to increased chemotherapy procedures. Myelosuppressive or Induction chemotherapy is anticipated to grow significantly due to growing pool of cancer patients. Pegfilgrastim stimulates the growth of healthy WBCs in the bone marrow, which helps fight any infection occurring post the chemotherapy procedure. The patients are heavily exposed to radiations which are poisonous and can damage the bone marrow. Therefore, the use of Pegfilgrastim Biosimilar in bone marrow transplantation is also anticipated to increase during the forecast period. Based on the distribution channels, hospital pharmacies will witness fastest growth in the Pegfilgrastim Biosimilar market.

Pegfilgrastim Biosimilar Market: Regional Outlook

North America’s Pegfilgrastim Biosimilar market is anticipated to grow at a rapid pace over the forecast period due to growing incidences of cancer, increase in health expenditure and easy affordability because of cost cuts. The Australia and New Zealand Pegfilgrastim Biosimilar market is anticipated to grow significantly owing to growth in the cases of acute chronic neutropenia, cancer and HIV/AIDS. Europe’s Pegfilgrastim Biosimilar market is expected to grow at a moderate rate over the forecast period owing to poor research and development investments by local governments, less GDP per capita and varying regulatory and competitive dynamics in different countries.

Request for Brochure @ https://www.factmr.com/connectus/sample?flag=B&rep_id=1494

Pegfilgrastim Biosimilar Market: Key Players

The first Pegfilgrastim Biosimilar product named Fulphila (Pegfilgrastim-jmdb) by Mylan-Biocon collaboration has been approved by US FDA and will soon be launched in the market. Other companies that have filed applications for Pegfilgrastim Biosimilar include USV Biologics, Cinfa Biotech, Coherus, Sandoz, Stada Arzneimittel/Gedeon Richter and Pfizer.

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

The report covers exhaustive analysis on:

Market Segments
Market Dynamics
Market Size
Supply & Demand
Current Trends/Issues/Challenges
Competition & Companies involved
Technology
Value Chain
Regional analysis includes

North America
US
Canada
Latin America
Brazil
Mexico
Argentina
Chile
Peru
Rest of LATAM
Europe
EU – 4 (Germany, France, Italy, Spain)
UK
BENELUX (Belgium, Netherlands, Luxemburg)
NORDIC (Norway, Denmark, Iceland, Sweden)
Eastern Europe (Poland, Ukraine, Czech Rep. Etc.)
Rest of Europe
CIS & Russia
Japan
APEJ
Greater China
India
Korea
ASEAN Countries
Rest of APEJ
Middle East & Africa
GCC Countries
Turkey
Iran
Israel
South Africa
Rest of MEA
Report Highlights:

Detailed overview of parent market
Changing market dynamics in the industry
In-depth market segmentation
Historical, current and projected market size in terms of volume and value
Recent industry trends and developments
Competitive landscape
Strategies of key players and products offered
Potential and niche segments, geographical regions exhibiting promising growth
A neutral perspective on market performance
Must-have information for market players to sustain and enhance their market footprint.

About Fact.MR

Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

Fact.MR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Pegfilgrastim Biosimilar Market to Witness a Pronounce Growth During 2018 to 2028 here

News-ID: 1177173 • Views:

More Releases from Fact.MR

Agricultural Film Market is forecasted to reach US$ 21 billion with 5.9% CAGR by the end of 2034
Agricultural Film Market is forecasted to reach US$ 21 billion with 5.9% CAGR by …
Fact.MR, a market research and competitive intelligence service, states that historically, the use of Agricultural Films grew at a 3.5% CAGR from 2016 to 2020, with the United States, China, India, and Japan holding a sizable portion of the global market. by 2021, the greenhouse film industry is expected to have grown to a valuation of over US$ 10 billion, largely due to price increases in agricultural films. For More Insights
Medical Equipment Rental Market is projected to expand at a CAGR of 5.5% to reach US$ 98 billion by 2033
04-25-2024 | Health & Medicine
Fact.MR
Medical Equipment Rental Market is projected to expand at a CAGR of 5.5% to reac …
The latest industry analysis from Fact.MR, a company that offers competitive intelligence and market research, projects that the global Medical Equipment Rental Market will grow at a 5.5% CAGR and reach US$ 98 billion in size by the end of 2033. The industry that deals with the short-term rental or lease of medical equipment to healthcare facilities, organizations, and individuals is known as the "medical equipment rental market." The goal of
Craft Beer Market is forecasted to reach a value of US$ 174.68 Billion by 2032
04-24-2024 | Food & Beverage
Fact.MR
Craft Beer Market is forecasted to reach a value of US$ 174.68 Billion by 2032
The worldwide craft beer market was expected to be worth $76.3 billion in 2020 and $81.64 billion in 2021. The market will grow at a steady CAGR of 6.9% between 2022 and 2032. By the end of 2032, this market is predicted to have a global valuation of US$174.68 billion. The surge in demand for more beer styles coupled with increase in per capita income among the target customers has triggered
Window Blinds Market Forecasted to Achieve US$ 4.69 Billion by 2034
Window Blinds Market Forecasted to Achieve US$ 4.69 Billion by 2034
The global window blinds market is expected to reach $2.99 billion in 2024, growing at a 5.8% CAGR to $4.69 billion by the end of 2034. Window blinds are adjustable window coverings made of slats or vanes, allowing for versatile control over light and privacy. They come in various materials, including wood, metal, or plastic, and can be easily adjusted to regulate sunlight and maintain privacy. Unlike heavy curtains, blinds are

All 5 Releases


More Releases for Pegfilgrastim

Pegfilgrastim Biosimilars Market 2021 : Trends, Business Growth And Major Drivin …
Get up to 33% off on ALL market research reports at The Business Research Company's holiday sale; buy now! https://www.thebusinessresearchcompany.com/global-market-reports ‘Pegfilgrastim Biosimilars Global Market Report 2021 – COVID-19 Growth And Change’ by The Business Research Company is the most comprehensive report available on this market, with analysis of the market’s historic and forecast growth, drivers and restraints causing this, and highlights of the opportunities that companies in the industry can take on.
05-04-2021 | Health & Medicine
Fact.MR
Pegfilgrastim Biosimilar Market to Exhibit 10% CAGR through 2026
Chemotherapy and/or radiotherapy is used for the treatment of most cancers. However, chemotherapy and radiotherapy have a very common side effect called neutropenia, and pegfilgrastim is required for its treatment. A study conducted on patients who received chemotherapy in 2016-2017 to evaluate the occurrence of chemotherapy-induced febrile neutropenia (CIFN) showed that, out of 200 patients, 9.5% patients developed neutropenia. Click HERE to Get Synopsis of the Report- https://www.factmr.com/report/1494/pegfilgrastim-biosimilar-market Neutropenia patients are highly
Global Pegfilgrastim Market to 2026 - Industry Perspective, Comprehensive Analys …
The Pegfilgrastim Market report is intended to function as a supportive means to assess the Pegfilgrastim market ( https://bit.ly/37xB0L8 ) along with the complete analysis and clear-cut statistics related to this market. In other words, the report would provide an up-to-date study of the market in terms of its latest trends, present scenario, and the overall market situation. Further, it will also help the clients in decision-making by presenting knowledgeable
Global Pegfilgrastim Market Analysis Report 2019-2024
This report on Global Pegfilgrastim Market details about the market size, market growth rate and global forecast for the next five years i.e. 2024. The report is a complete analysis assessing the pricing trends, market consumption and sales forecasts. This study covers the competitive landscape by profiling the major market players. The vital information of the market is collected through authentic sources and reviewed by industry experts. Pegfilgrastim is a PEGylated
Pegfilgrastim Biosimilar Market: Industry Trends and Developments 2018-2028
Biosimilar is a medical product that is almost an identical copy of an existing drug manufactured by a different company. They require independent approval through clinical trials. The Biosimilar market is an expanding market. Approximately 30% of drugs sold globally are biopharma drugs. 40% of prescription drug spending in the US is on biologic drugs. Filgrastim is used as a medication for treating low levels of blood neutrophils caused by
Pegfilgrastim Biosimilar Market Estimated to Record Highest CAGR by 2018 to 2028
Biosimilar is a medical product that is almost an identical copy of an existing drug manufactured by a different company. They require independent approval through clinical trials. The Biosimilar market is an expanding market. Approximately 30% of drugs sold globally are biopharma drugs. 40% of prescription drug spending in the US is on biologic drugs. Filgrastim is used as a medication for treating low levels of blood neutrophils caused by